Biosensing Startup Xsensio Raises $7M

The new funding for Xsensio is earmarked for the clinical validation and accelerated development of its "Lab-on-Skin" wearable biosensing platform. This technology aims to provide continuous, real-time biochemical data to support clinical decisions in hospital settings and beyond. The company is also entering a long-term collaboration with Texas Instruments, a move that will leverage the semiconductor giant's expertise in large-scale manufacturing and miniaturization. The investment was led by WI Harper Group, a San Francisco-based venture capital firm with a history of backing deep-tech and healthcare companies. With over $1 billion in committed capital, WI Harper focuses on cross-border investments between the US and Asia, signaling a global ambition for Xsensio's technology. Other investors in the round included Privilège Ventures and the European Innovation Council. Xsensio's core technology originated at the Nanolab of the Swiss Federal Institute of Technology. Its platform utilizes a highly miniaturized sensing chip to detect biomarkers such as metabolites, proteins, and hormones in the interstitial fluid just beneath the skin. The initial focus for this technology is the early detection of organ dysfunction in critical care, oncology, and post-surgical recovery. This funding follows a history of strategic investments and collaborations for Xsensio, which was founded in 2014. In February 2023, the company announced a know-how and stock purchase agreement with the Mayo Clinic to advance its technology for critical care. Previous funding rounds have included investors like DART Ventures and Privilege Ventures. The market for biochemical sensors is expanding rapidly, with projections indicating it could grow from over $21.5 billion in 2023 to more than $52 billion by 2033. This growth is driven by the increasing demand for personalized medicine and real-time health monitoring. The broader continuous monitoring market in healthcare is also seeing significant investment, with a projected market size of over $4.8 billion in 2025. Xsensio is entering a competitive landscape of wearable biosensor companies. Its approach of analyzing interstitial fluid differs from competitors like Withings, Ultrahuman, and Oura, which primarily focus on other physiological signals. This focus on biochemical data provides a more direct window into the body's metabolic functions.